Switch theme
Sign up to access all valuation multiples
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
1992
401
LTM Revenue $61.6M
Last FY EBITDA -$16.9M
$126M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Trinity Biotech has a last 12-month revenue (LTM) of $61.6M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Trinity Biotech achieved revenue of $61.6M and an EBITDA of -$16.9M.
Trinity Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Trinity Biotech valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $61.6M | XXX | $61.6M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $21.4M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 35% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$16.9M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -27% | XXX | XXX | XXX |
| EBIT | n/a | XXX | -$15.5M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | -25% | XXX | XXX | XXX |
| Net Profit | -$31.8M | XXX | -$31.8M | XXX | XXX | XXX |
| Net Margin | -52% | XXX | -52% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $82.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 15, 2025, Trinity Biotech's stock price is $2.
Trinity Biotech has current market cap of $30.2M, and EV of $126M.
See Trinity Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $126M | $30.2M | XXX | XXX | XXX | XXX | $-1.74 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 15, 2025, Trinity Biotech has market cap of $30.2M and EV of $126M.
Trinity Biotech's trades at 2.0x EV/Revenue multiple, and -7.4x EV/EBITDA.
Equity research analysts estimate Trinity Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Trinity Biotech has a P/E ratio of -0.9x.
See valuation multiples for Trinity Biotech and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $30.2M | XXX | $30.2M | XXX | XXX | XXX |
| EV (current) | $126M | XXX | $126M | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -7.4x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -8.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.9x | XXX | -0.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -8.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTrinity Biotech's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Trinity Biotech's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Trinity Biotech's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Trinity Biotech and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -27% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 60% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Trinity Biotech acquired XXX companies to date.
Last acquisition by Trinity Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Trinity Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Trinity Biotech founded? | Trinity Biotech was founded in 1992. |
| Where is Trinity Biotech headquartered? | Trinity Biotech is headquartered in United States of America. |
| How many employees does Trinity Biotech have? | As of today, Trinity Biotech has 401 employees. |
| Who is the CEO of Trinity Biotech? | Trinity Biotech's CEO is Mr. John Gillard. |
| Is Trinity Biotech publicy listed? | Yes, Trinity Biotech is a public company listed on NAS. |
| What is the stock symbol of Trinity Biotech? | Trinity Biotech trades under TRIB ticker. |
| When did Trinity Biotech go public? | Trinity Biotech went public in 1992. |
| Who are competitors of Trinity Biotech? | Similar companies to Trinity Biotech include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Trinity Biotech? | Trinity Biotech's current market cap is $30.2M |
| What is the current revenue of Trinity Biotech? | Trinity Biotech's last 12 months revenue is $61.6M. |
| What is the current EV/Revenue multiple of Trinity Biotech? | Current revenue multiple of Trinity Biotech is 2.0x. |
| Is Trinity Biotech profitable? | Yes, Trinity Biotech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
